49. Systemic lupus erythematosus Clinical trials / Disease details
Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02953821 (ClinicalTrials.gov) | December 16, 2016 | 1/11/2016 | Acthar Gel for Active Systemic Lupus Erythematosus (SLE) | A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids | Lupus Erythematosus, Systemic | Drug: Acthar Gel;Drug: Placebo Gel | Mallinckrodt | NULL | Completed | 18 Years | N/A | All | 172 | Phase 4 | United States;Argentina;Chile;Mexico;Peru;Colombia |
| 2 | NCT02779153 (ClinicalTrials.gov) | October 2016 | 18/5/2016 | Acthar SLE (Systemic Lupus Erythematosus) | Efficacy, Safety, and Steroid Sparing Effect of Acthar in Patients With Hematologic Manifestations of Systemic Lupus Erythematosus | Systemic Lupus Erythematosus (SLE);Repository Corticotropin Injection | Drug: Acthar low dose (40 U);Drug: Acthar high dose (80 U) | NYU Langone Health | Mallinckrodt | Withdrawn | 18 Years | N/A | All | 0 | Phase 4 | United States |
| 3 | NCT01753401 (ClinicalTrials.gov) | January 2013 | 17/12/2012 | Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease | A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease | Systemic Lupus Erythematosus (SLE) | Drug: Acthar;Drug: Placebo;Drug: Steroid Drug | Mallinckrodt | NULL | Completed | 18 Years | N/A | All | 38 | Phase 4 | United States |
| 4 | NCT01769937 (ClinicalTrials.gov) | October 2012 | 15/1/2013 | Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus | A Single-site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection)an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) | Lupus Erythematosus Systemic Exacerbation | Drug: H.P. Acthar Gel | Fiechtner, Justus J., M.D., P.C. | NULL | Completed | 18 Years | 75 Years | Both | 10 | Phase 4 | United States |